21.03.2022 • News

BMS Sues Astra Zeneca in Cancer Drug Patent Row

Bristol-Myers Squibb (BMS) is suing AstraZeneca Pharmaceuticals, alleging that the Anglo-Swedish drugmaker’ Imfinzi to treat lung and bladder cancer infringes several patents related to its blockbuster Opdivo.

The patent dispute is being heard by a federal court in the US state of Delaware. News agency reports said BMS Is seeking financial damages of an undisclosed amount. Neither company has commented on the litigation.

The New York drugmaker’s immunotherapy patents relate to a monoclonal antibody used to destroy cancer cells. Opdivo is used to treat cancers of the lung and bladder as well as melanoma and Hodgkin lymphoma.

According to a filing with the US Securities and Exchange Commission quoted by Reuters, BMS took in worldwide sales of more than $7.5 billion from Opdivo in 2021. AstraZeneca reported sales of more than $2.4 billion for Imfinzi the same year.

Author: Dede Williams, Freelance Journalist

(c) AstraZeneca
(c) AstraZeneca

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.